- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01487863
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects underwent screening procedures at the Screening Visit to ensure that they met the inclusion and exclusion criteria outlined in the protocol. Subjects were evaluated for eligibility criteria, and if eligible, were registered and randomized in a 1:1 into either the Concurrent Arm or the Sequential Arm.
Subjects in both arms underwent a standard 1.5 to 2.0 blood volume leukapheresis, followed approximately 3 days later by an intravenous (IV) infusion of sipuleucel-T. This process occurred at approximately 2-week intervals. A course of sipuleucel-T treatment comprised three infusions.
Following the first infusion, subjects were limited to a maximum of three total product failures for all subsequent infusions, due specifically to insufficient total nucleated cell (TNC) count and/or CD54 upregulation. These subjects received no further leukaphereses or sipuleucel-T infusions, but did receive abiraterone acetate plus prednisone per the schedule of the arm to which they were randomized. All subjects received a total of 26 weeks of abiraterone acetate plus prednisone therapy.
All immune monitoring (IM) endpoints were collected from all subjects who received at least one infusion. Cellular and serological immune responses were assessed for subjects in both arms. In both arms, IM blood samples were collected at baseline (screening); pre-leukapheresis 2 and 3; post-infusion 1, 2, and 3; and weeks 6, 10, 14, and 26, with the timing of IM visits based on the onset of treatment (Day 0). Day 0 was the day of the first infusion. Post-infusion blood draws occurred at 3 hours (allowable window 1-24 hours) after each infusion. If a subject received only one or two infusions, immune samples were still drawn at the scheduled time points based on the first infusion (Day 0). If the subject was not scheduled to undergo further leukapheresis, no other pre-leukapheresis procedures were conducted.
During the active follow-up phase, subjects were followed from registration through the Post-Treatment Visit (30-37 days post-last study treatment), or until disease progression, unacceptable toxicity, or death, whichever occurred first.
During the long-term follow-up (LTFU) phase, subjects were followed from the Post-Treatment Visit for up to 3 years from the date of registration/randomization. During the LTFU phase, only new treatment-related serious adverse event (SAE)s, cerebrovascular event (CVE)s (regardless of causality), the first anti-cancer therapy and first chemotherapy, and survival status were collected via a quarterly telephone call.
Overall survival was measured as the time from randomization until death over a 3-year period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Moores UCSD Cancer Center
-
La Jolla, California, United States, 92037
- UCSD Medical Center - La Jolla
-
La Mesa, California, United States, 91942
- Cancer Center Oncology Medical Group
-
San Diego, California, United States, 92123
- Medical Oncology Associates - Sd
-
San Diego, California, United States, 92123
- Sharp Rees-Stealy
-
San Diego, California, United States, 92103
- UCSD Medical Center - Hillcrest
-
San Francisco, California, United States, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, United States, 80211
- The Urology Center of Colorado
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center - Lombardi Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Maryland
-
Greenbelt, Maryland, United States, 20770
- Mid Atlantic Urology Associates, Mid Atlantic Clinical Research
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- GU Research Center, LLC
-
-
New York
-
New York, New York, United States, 10029
- The Mount Sinai Medical Center
-
New York, New York, United States, 10016
- NYU Clinical Cancer Center, NYU Langone Medical Center
-
Oneida, New York, United States, 13421
- Associated Medical Professionals of NY, PLLC
-
Syracuse, New York, United States, 13210
- Associated Medical Professionals of New York, PLLC
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Center Oncology And Hematology Care
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37209
- Urology Associates, P.C.
-
-
Virginia
-
Virginia Beach, Virginia, United States, 23462
- Urology of Virginia
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically documented prostate cancer confirmed by a pathology report from prostate biopsy or radical prostatectomy specimen
- metastatic status as evidenced by imaging obtained </= 56 days prior to registration demonstrating bone metastasis or lymph node metastasis
- castrate resistant prostate cancer: castrate levels of testosterone (</= 50 ng/dL); evidence of disease progression concomitant with surgical or medical castration
- serum PSA >/= 2.0 ng/mL
- castrate levels of testosterone (</= 50 ng/dL) achieved via medical or surgical castration
- baseline Eastern Cooperative Oncology Group (ECOG) performance status of </= 1
- systolic blood pressure (BP) </= 140 mm Hg and diastolic BP </= 90 mm Hg at screening
- adequate baseline hematologic, renal, and liver functions
- must live in a permanent residence within a comfortable driving distance (round trip within one day) of the clinical trial site
Exclusion Criteria:
- the presence of known lung, liver, or brain metastases, malignant pleural effusions, or malignant ascites
- New York Heart Association Class III or IV heart failure
- any medical condition that may be compromised by increases in blood pressure, hypokalemia, or fluid retention
- Child-Pugh Class B or C hepatic insufficiency
- spinal cord compression, imminent long bone fracture, or any other condition likely to require radiation therapy and/or steroids for pain control
- known adrenalcortical insufficiency
- any medical contraindications to receiving prednisone
- prior treatment with sipuleucel-T
- previous treatment with abiraterone acetate (Zytiga(R)) or ipilimumab (Yervoy(TM))
- a requirement for systemic immunosuppressive therapy for any reason. Use of inhaled, intra-nasal, intra-articular, and topical steroids was allowed.
- treatment with any investigational vaccine or immunotherapy
- treatment with any chemotherapy prior to registration.
- a history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years at the time of registration.
- myocardial infarction or ventricular or atrial arrhythmia within 6 months prior to registration
- ongoing anti-androgen withdrawal response.
- systemic steroid use within ≤ 60 days of registration
- treatment with denosumab (Xgeva(R) or Prolia (R)) within ≤ 3 months prior to registration
- positive test for human immunodeficiency virus (HIV) or human T cell lymphotrophic virus (HTLV) infections. Subjects with a positive test for hepatitis B or hepatitis C were allowed provided they meet the liver function test (LFT) criteria and have no signs of acute infection or active disease.
- treatment with any of the following medications or interventions within 28 days prior to registration: external beam radiation or major surgery requiring general anesthetic; saw palmetto; megestrol acetate (Megace(R)), diethylstilbestrol, and cyproterone; 5-alpha-reductase inhibitors (e.g. finasteride [Proscar(R)], dutasteride [Avodart(R)]); steroidal anti-androgen therapy; any other systemic therapy for prostate cancer, except for medical castration; treatment with any other investigational product for prostate cancer; substrates of CYP2D6 (e.g. including but not limited to thioridazine); inhibitors of CYP3A4 (e.g. including but not limited to ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin, and voriconazole); inducers of CYP3A4 (e.g. including but not limited to phenytoin, carbamazepine, rifampin, rifapentine, and phenobarbital)
- a requirement for treatment with opioid analgesics within 21 days prior to registration
- an active infection or infection requiring parenteral antibiotic therapy or causing fever within 7 days of registration
- any medical intervention, or other condition, or any other circumstance that, in the opinion of the Investigator or the Dendreon Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study's objectives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Concurrent Arm
Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone.
Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
|
Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Other Names:
Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
Other Names:
|
Experimental: Sequential Arm
Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone.
Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
|
Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Other Names:
Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative CD54 Upregulation Ratio Between the Cohorts.
Time Frame: Over the course of sipuleucel-T therapy (approximately 1 month)
|
An analysis of variance model for the log transformed cumulative CD54 upregulation ratio (CD54 upregulation is the fold increase in the final product (FP) from buoyant density separations (BDS) step 65.
BDS65 step refers to sample taken after both BDS77 and BDS65 but before ex vivo culture in the presence of antigen PA2024.
FP refers to sample taken after ex vivo culture) that includes the antigen concentration cohort as the independent variable was performed.
Subjects who received all 3 infusions were included.
|
Over the course of sipuleucel-T therapy (approximately 1 month)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- immunotherapy
- prostate cancer
- vaccine
- androgen independent
- abiraterone
- cancer vaccine
- prostate
- sequencing
- hormone refractory
- prostatic adenocarcinoma
- immune therapy
- dendritic cells
- prednisone
- antigen-presenting cells
- antigen presenting cells
- therapeutic vaccine
- androgen independent prostate cancer (AIPC)
- androgen-independent
- hormone insensitive
- hormone-insensitive
- prostate specific antigen (PSA)
- hormone-refractory
- hormone refractory prostate cancer (HRPC)
- therapeutic cancer vaccine
- recombinant
- biological
- biopharmaceutical
- biotechnology
- biotech
- castration resistant prostate cancer (CRPC)
- castration-resistant prostate cancer (CRPC)
- castration-resistance
- sipuleucel-T
- sequence
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Abiraterone Acetate
Other Study ID Numbers
- P11-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone Refractory Prostate Cancer
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupAstellas Pharma Inc; Apices Soluciones S.L.CompletedHormone-refractory Prostate CancerSpain
-
Peking UniversityWithdrawnHormone Refractory Prostate CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownHormone Refractory Prostate CancerChina
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
British Columbia Cancer AgencyCompletedHormone Refractory Prostate CancerCanada
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
Clinical Trials on sipuleucel-T
-
DendreonUniversity of California, San FranciscoCompleted
-
DendreonCompletedProstatic Neoplasms | Advanced Prostate CancerUnited States
-
DendreonTerminatedProstate CancerUnited States
-
DendreonNot yet recruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bayer; DendreonCompletedProstate CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedmCRPC | Metastatic Castrate-resistant Prostate CancerUnited States
-
DendreonPRA Health SciencesActive, not recruitingAdenocarcinoma of the ProstateUnited States
-
DendreonCompletedProstate CancerUnited States
-
DendreonCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateAustria, France, Netherlands, United Kingdom
-
DendreonCompletedHormone-Refractory Prostate Cancer